Embera NeuroTherapeutics Overview

  • Founded
  • 2007
Founded
  • Status
  • Private
  • Employees
  • 5
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $6.13M
Latest Deal Amount
  • Investors
  • 14

Embera NeuroTherapeutics General Information

Description

Provider of medication intended to treat addiction by moderating activity in the stress response system. The company's medication reduces the cravings and loss of control that drive addiction by targeting multiple pathways, to maximize potential efficacy more than either drug used alone, enabling users to abstain from smoking and drug use.

Contact Information

Website
www.emberaneuro.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 29 Babe Ruth Drive
  • Suite 210
  • Sudbury, MA 01776
  • United States
+1 (978) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Embera NeuroTherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC (Series B) 01-Aug-2020 $6.13M 000.00 000.00 Completed Clinical Trials - Phase 2
9. Grant 26-Jul-2016 000.00 000.00 Completed Clinical Trials - Phase 1
8. Later Stage VC (Series B) 29-Jan-2016 00.00 000.00 0000 Completed Clinical Trials - Phase 1
7. Accelerator/Incubator 05-Aug-2015 0000 Completed Generating Revenue
6. Later Stage VC (Series A2) 26-Feb-2015 00.000 0000 000.00 Completed Generating Revenue
5. Grant 01-Jul-2014 00.00 00.00 Completed Generating Revenue
4. Early Stage VC (Series A2) 15-Aug-2011 00.00 00.00 00.000 Completed Startup
3. Early Stage VC (Series A) 03-Sep-2008 000 00.000 Completed Startup
2. Early Stage VC (Series A1) 25-Aug-2008 $1.36M $1.96M 0000 Completed Startup
1. Early Stage VC (Series A) 23-Jan-2007 $600K $600K Completed Startup
To view Embera NeuroTherapeutics’s complete valuation and funding history, request access »

Embera NeuroTherapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.00
Series A2 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A1 1,357,100 $0.001000 $0.06 $1 $1 1x $1 3.74%
To view Embera NeuroTherapeutics’s complete cap table history, request access »

Embera NeuroTherapeutics Patents

  • 37

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 2

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Embera NeuroTherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200360400-A1 Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease Pending 19-May-2017 0000000000
AU-2018230521-A1 Pharmaceutical compositions and uses thereof Pending 10-Mar-2017 0000000000
US-11179377-B2 Pharmaceutical compositions and uses thereof Active 10-Mar-2017 0000000000 000
US-20200054615-A1 Pharmaceutical compositions and uses thereof Granted 10-Mar-2017 0000000000
JP-2020511455-A Pharmaceutical composition and use thereof Pending 10-Mar-2017 A61K9/1611 0
To view Embera NeuroTherapeutics’s complete patent history, request access »

Embera NeuroTherapeutics Executive Team (12)

Name Title Board Seat Contact Info
Gary Connor Chief Operating Officer & Vice President of Clinical Operations
Douglas Feltner Founder & Development Advisory Board Member
Julie Straub Ph.D Vice President, CMC and Nonclinical Development
Ann Robbins Ph.D Vice President, Regulatory Affairs
Bruce McCarthy MD Chief Medical Officer
You’re viewing 5 of 12 executive team members. Get the full list »

Embera NeuroTherapeutics Board Members (8)

Name Representing Role Since
Dennis Purcell Self Board Member 000 0000
Douglas Feltner Embera NeuroTherapeutics Founder & Development Advisory Board Member 000 0000
Franz Hefti Ph.D Self Board Member 000 0000
John Beaird Self Board Member 000 0000
Joseph Lovett Louisiana Funds Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Embera NeuroTherapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Embera NeuroTherapeutics Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Seven Funds Venture Capital Minority 000 0000 000000 0
ROSE RESEARCH CENTER, LLC Corporation 000 0000 000000 0
Keiretsu Forum Venture Capital Minority 000 0000 000000 0
NO/LA Angel Network Angel Group Minority 000 0000 000000 0
Technomark Life Sciences Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

Ready to get started?

Request a free trial